Journal of Clinical Endocrinology & Metabolism, Vol 72, 1184-1188, Copyright © 1991 by Endocrine Society

ARTICLES

A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma

T Diamond, L Nery and I Hales
Department of Endocrinology, St. George Hospital, Kogarah, Sydney, Australia.

We measured lumbar spine, femoral neck, and forearm bone mineral (BMD) in 24 women (14 premenopausal and 10 postmenopausal) who had been treated with total thyroidectomy and 131 Iodine ablation therapy for nonanaplastic thyroid carcinoma and 24 case controls. At the time of the study, all patients were free of cancer (negative 131 Iodine whole body scan and serum thyroglobulin levels less than 0.3 micrograms/L) and all were receiving doses of T4 sufficiently high to prevent a rise in a serum thyroid-stimulating hormone concentration after an iv bolus of TRH. Femoral neck BMD were significantly reduced in both the premenopausal women (89 +/- 3.8% of case controls, 95% CI, 81 to 98) and postmenopausal women (77 +/- 3.9% of case controls; 95% CI, 68 to 86) receiving T4. Lumbar spine BMD and forearm BMD were unaffected in the premenopausal women, but significantly reduced in the postmenopausal women receiving T4 (lumbar spine BMD = 84 +/- 6.2% of case controls; 95% CI, 70 to 98 and forearm BMD = 89 +/- 5.6% of case controls; 95% CI, 76 to 101). Serum bone Gla-protein, a marker of bone turnover, was significantly increased in both the premenopausal and the postmenopausal women receiving T4 compared to case controls (P less than 0.001 for the difference between patient groups and controls). Whereas the cumulative dose of T4 was highly correlated with the femoral neck BMD in the premenopausal patients (r = 0.528; P less than 0.05); the presence of hypogonadism was the main determinant of the lumbar spine and forearm BMD. This data confirms that premenopausal and postmenopausal women receiving suppressive doses of T4 for thyroid carcinoma have diminished bone mineral measurements and are at risk for osteoporosis.

This article has been cited by other articles:

				B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]

				L. B. Michaud and S. Goodin Cancer-treatment-induced bone loss, part 1 Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 419 - 430. [Abstract] [Full Text] [PDF]

				A C. Heijckmann, M. S P Huijberts, P. Geusens, J. de Vries, P. P C A Menheere, and B. H R Wolffenbuttel Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma Eur. J. Endocrinol., July 1, 2005; 153(1): 23 - 29. [Abstract] [Full Text] [PDF]

				A C Al-Abadi Subclinical thyrotoxicosis Postgrad. Med. J., January 1, 2001; 77(903): 29 - 29. [Full Text]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				Levothyroxine Suppression of Thyroglobulin in Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4549 - 4553. [Abstract] [Full Text]

				H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]

				M. Milne, M.-I. Kang, J. M. Quail, and D. T. Baran Thyroid Hormone Excess Increases Insulin-Like Growth Factor I Transcripts in Bone Marrow Cell Cultures: Divergent Effects on Vertebral and Femoral Cell Cultures Endocrinology, May 1, 1998; 139(5): 2527 - 2534. [Abstract] [Full Text] [PDF]

				D. C. Bauer, M. C. Nevitt, B. Ettinger, and K. Stone Low Thyrotropin Levels Are Not Associated with Bone Loss in Older Women: A Prospective Study J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2931 - 2936. [Abstract] [Full Text] [PDF]

				E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada, J. D. Luna, and N. Olea Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1989 - 1994. [Abstract] [Full Text] [PDF]

				A. D. Toft Thyroxine Therapy N. Engl. J. Med., July 21, 1994; 331(3): 174 - 180. [Full Text]

				E. L. Mazzaferri Management of a Solitary Thyroid Nodule N. Engl. J. Med., February 25, 1993; 328(8): 553 - 559. [Full Text]